Aadi Bioscience reports Q2 EPS (54c), consensus (69c)

Reports Q2 revenue $6.2M, consensus $6.2M. Cash, cash equivalents and short-term investments as of June 30 were $78.6M million as compared to $108.8M as of December 31, 2023, which is expected to fund operations into Q4 2025 based on current plans. “The Q2 saw quarter over quarter sales growth for FYARRO, as anticipated, and an increase in demand across both new and existing accounts, including from major oncology centers. Approximately 80% of accounts have ordered multiple times already this year, reflecting the clinical value of FYARRO for patients with advanced malignant PEComa,” said Dave Lennon, President and CEO of Aadi Bioscience. “Looking ahead, we will provide the next interim update from PRECISION1, a tumor-agnostic study that enrolled any tumor type presenting with qualifying TSC1 or TSC2 inactivating alterations, later in the third quarter. With this study, nab-sirolimus has the potential to demonstrate a meaningful impact on the lives of patients who have already received standard therapies appropriate for their tumor type and stage of disease.”